-
1Academic Journal
Συγγραφείς: E. V. Pronin, V. S. Pronin, M. B. Antsiferov, A. V. Petryaykin, T. M. Alexeeva, A. M. Lapshina, L. S. Urusova, A. N. Khoruzhaya, S. M. Tamaeva, Е. В. Пронин, В. С. Пронин, М. Б. Анциферов, А. В. Петряйкин, Т. М. Алексеева, А. М. Лапшина, Л. С. Урусова, А. Н. Хоружая, С. М. Тамаева
Πηγή: Meditsinskiy sovet = Medical Council; № 6 (2024); 98-111 ; Медицинский Совет; № 6 (2024); 98-111 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: пэгвисомант, somatotrophic tumors, precision medicine, T2-weighted MRI, T1-weighted MRI, (T2-T1)-weighted MRI, drug therapy, first-generation somatostatin receptor ligands, pegvisomant, соматотрофные опухоли, прецизионная медицина, 2-й подтип соматостатиновых рецепторов, фиброзные тельца, Т2-взвешенные изображения, Т1-взвешенные изображения, (Т2-Т1)-взвешенные изображения, медикаментозная терапия, аналоги соматостатина 1-го поколения
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8273/7295; Asa SL, Kucharczyk W, Ezzat S. Pituitary acromegaly: not one disease. Endocr Relat Cancer. 2017;24(3):C1–C4. https://doi.org/10.1530/erc-16-0496.; Lenders NF, Earls PE, Inder WJ, McCormack AI. The evolution in pituitary tumour classification: a clinical perspective. Endocr Oncol. 2023;3(1):e220079. https://doi.org/10.1530/EO-22-0079.; Asa SL. Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors. Endocr Pathol. 2021;32(2):222–227. https://doi.org/10.1007/s12022-021-09678-x.; Lee CH. Pituitary Neuroendocrine Tumor: Is It Benign or Malignant? Brain Tumor Res Treat. 2023;11(3):173–176. https://doi.org/10.14791/btrt.2023.0015.; Mete O, Wenig BM. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms. Head Neck Pathol. 2022;16(1):123–142. https://doi.org/10.1007/s12105-022-01435-8.; Swanson AA, Erickson D, Donegan DM, Jenkins SM, Van Gompel JJ, Atkinson JLD et al. Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly. Pituitary. 2021;24(2):192–206. https://doi.org/10.1007/s11102-020-01096-2.; Mete O, Asa SL. Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. Endocr Pathol. 2020;31(4):330–336. https://doi.org/10.1007/s12022-020-09646-x.; Liu X, Dai C, Feng M, Li M, Chen G, Wang R. Diagnosis and treatment of refractory pituitary adenomas: a narrative review. Gland Surg. 2021;10(4):1499–1507. https://doi.org/10.21037/gs-20-873.; Akirov A, Asa SL, Amer L, Shimon I, Ezzat S. The Clinicopathological Spectrum of Acromegaly. J Clin Med. 2019;8(11):1962. https://doi.org/10.3390/jcm8111962.; Ferrés A, Reyes L, Di Somma A, Topczewski T, Mosteiro A, Guizzardi G et al. The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up. Cancers (Basel). 2022;15(1):267. https://doi.org/10.3390/cancers15010267.; Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021;24(1):1–13. https://doi.org/10.1007/s11102-020-01091-7.; Remba-Shapiro I, Nachtigall LB. Treatment of acromegaly with oral octreotide. Best Pract Res Clin Endocrinol Metab. 2024:101888. https://doi.org/10.1016/j.beem.2024.101888.; Puig-Domingo M, Gil J, Sampedro-Nuñez M, Jordà M, Webb SM, Serra G et al. Molecular profiling for acromegaly treatment: a validation study. Endocr Relat Cancer. 2020;27(6):375–389. https://doi.org/10.1530/ERC-18-0565.; Ku CR, Melnikov V, Zhang Z, Lee EJ. Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality? Endocrinol Metab (Seoul). 2020;35(2):206–216. https://doi.org/10.3803/EnM.2020.35.2.206.; Kasuki L, Lamback E, Antunes X, Gadelha MR. Biomarkers of response to treatment in acromegaly. Expert Rev Endocrinol Metab. 2024;19(1):71–80. https://doi.org/10.1080/17446651.2023.2293107.; Găloiu S, Toma ID, Tănasie DI, Bărbulescu A, Baciu I, Niculescu DA et al. High mortality risk among women with acromegaly still persists. Front Endocrinol (Lausanne). 2024;15:1348972. https://doi.org/10.3389/fendo.2024.1348972.; Gil J, Marques-Pamies M, Sampedro M, Webb SM, Serra G, Salinas I et al. Data mining analyses for precision medicine in acromegaly: a proof of concept. Sci Rep. 2022;12(1):8979. https://doi.org/10.1038/s41598-022-12955-2.; Berton AM, Prencipe N, Bertero L, Baldi M, Bima C, Corsico M et al. Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study. J Clin Med. 2022;12(1):25. https://doi.org/10.3390/jcm12010025.; Fleseriu M, Führer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J et al. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol. 2021;185(4):525–538. https://doi.org/10.1530/EJE-21-0239.; Soukup J, Hornychova H, Manethova M, Michalova K, Michnova L, Popovska L et al. Predictive and prognostic significance of tumour subtype, SSTR1-5 and e-cadherin expression in a well-defined cohort of patients with acromegaly. J Cell Mol Med. 2021;25(5):2484–2492. https://doi.org/10.1111/jcmm.16173.; Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol. 2008;19(2):82–91. https://doi.org/10.1007/s12022-008-9029-z.; Asa SL, Ezzat S. An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism. J Clin Med. 2021;10(11):2254. https://doi.org/10.3390/jcm10112254.; Kasuki L, Gadelha MR. Innovative therapeutics in acromegaly. Best Pract Res Clin Endocrinol Metab. 2022;36(6):101679. https://doi.org/10.1016/j.beem.2022.101679.; Coopmans EC, Schneiders JJ, El-Sayed N, Erler NS, Hofland LJ, van der Lely AJ et al. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. Eur J Endocrinol. 2020;182(6):595–605. https://doi.org/10.1530/EJE-19-0840.; Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab. 2010;95(11):4973–4978. https://doi.org/10.1210/jc.2010-0573.; Kocak B, Durmaz ES, Kadioglu P, Polat Korkmaz O, Comunoglu N, Tanriover N et al. Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. Eur Radiol. 2019;29(6):2731–2739. https://doi.org/10.1007/s00330-018-5876-2.; Liu CX, Wang SZ, Heng LJ, Han Y, Ma YH, Yan LF et al. Predicting Subtype of Growth Hormone Pituitary Adenoma based on Magnetic Resonance Imaging Characteristics. J Comput Assist Tomogr. 2022;46(1):124–130. https://doi.org/10.1097/RCT.0000000000001249.; Tang Y, Xie T, Guo Y, Liu S, Li C, Liu T et al. Analysis of Diffusion-Weighted and T2-Weighted Imaging in the Prediction of Distinct Granulation Patterns of Somatotroph Adenomas. World Neurosurg. 2024;182:e334–e343. https://doi.org/10.1016/j.wneu.2023.11.107.; Scânteie CL, Leucuţa DC, Ghervan C. The therapeutic response of somatotropinomas according to the T2-weighted signal intensity on the MRI. Med Pharm Rep. 2021;94(4):425–433. https://doi.org/10.15386/mpr-1299.; Анциферов МБ, Петряйкин АВ, Алексеева ТМ, Пронин ЕВ, Хоружая АН, Тамаева СМ. Современные возможности опухоль-ориентированной диагностики и лечения акромегалии. Фарматека. 2023;(3):78–88. https://doi.org/10.18565/pharmateca.2023.3.78-88.; Marques-Pamies M, Gil J, Jordà M, Puig-Domingo M. Predictors of Response to Treatment with First-Generation Somatostatin Receptor Ligands in Patients with Acromegaly. Arch Med Res. 2023;54(8):102924. https://doi.org/10.1016/j.arcmed.2023.102924.; Durmuş ET, Atmaca A, Kefeli M, Çalışkan S, Mete O, Aslan K et al. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study. Growth Horm IGF Res. 2022;67:101502. https://doi.org/10.1016/j.ghir.2022.101502.; Tomasik A, Stelmachowska-Banaś M, Maksymowicz M, Czajka-Oraniec I, Raczkiewicz D, Zieliński G et al. Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly. Front Endocrinol (Lausanne). 2022;13:957301. https://doi.org/10.3389/fendo.2022.957301.; Biagetti B, Iglesias P, Villar-Taibo R, Moure MD, Paja M, Araujo-Castro M et al. Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain. Front Endocrinol (Lausanne). 2022;13:984877. https://doi.org/10.3389/fendo.2022.984877.; Giustina A, di Filippo L, Uygur MM, Frara S. Modern approach to resistant acromegaly. Endocrine. 2023;80(2):303–307. https://doi.org/10.1007/s12020-023-03317-7.; Pronin VS, Antsiferov MB, Alexeeva TM, Pronin EV. Using a Precision Approach to Optimize the Drug Therapy of Patients With Acromegaly Syndrome. In: Ahmad M (ed.). The Pituitary Gland – An Overview of Pathophysiology and Current Management Techniques. London: IntechOpen; 2023, pp. 25–44. https://doi.org/10.5772/intechopen.1001376.; Ezzat S, Caspar-Bell GM, Chik CL, Denis MC, Domingue MÈ, Imran SA et al. Predictive markers for postsurgical medical management of acromegaly: a systematic review and consensus treatment guideline. Endocr Pract. 2019;25(4):379–393. https://doi.org/10.4158/EP-2018-0500.; Ezzat S, Wang R, Pintilie M, Asa SL. FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors. Oncotarget. 2017;8(2):3481–3494. https://doi.org/10.18632/oncotarget.13843.; Chiloiro S, De Marinis L. The immune microenviroment in somatotropinomas: from biology to personalized and target therapy. Rev Endocr Metab Disord. 2023;24(2):283–295. https://doi.org/10.1007/s11154-022-09782-1.; Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metab. 2010;95(5):2334–2342. https://doi.org/10.1210/jc.2009-2197.; Nishioka H, Haraoka J, Akada K. Fibrous bodies are associated with lower GH production and decreased expression of E-cadherin in GH-producing pituitary adenomas. Clin Endocrinol (Oxf). 2003;59(6):768–772. https://doi.org/10.1046/j.1365-2265.2003.01921.x.; Gil J, Marques-Pamies M, Valassi E, García-Martínez A, Serra G, Hostalot C et al. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response. Biomedicines. 2022;10(2):460. https://doi.org/10.3390/biomedicines10020460.; Gliga MC, Tătăranu LG, Popescu M, Chinezu L, Paşcanu MI. Immunohistochemical evaluation of biomarkers with predictive role in acromegaly: a literature review. Rom J Morphol Embryol. 2023;64(1):25–33. https://doi.org/10.47162/RJME.64.1.03.; Alhambra-Expósito MR, Ibáñez-Costa A, Moreno-Moreno P, Rivero-Cortés E, Vázquez-Borrego MC, Blanco-Acevedo C et al. Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. Sci Rep. 2018;8(1):6173. https://doi.org/10.1038/s41598-018-24260-y.; Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2013;98(1):E66–E71. https://doi.org/10.1210/jc.2012-2609.; Wang L, He X, Lu L, Chen L, Peng C, Shao C, Ge R. Clinicopathological Analysis of Densely and Sparsely Granulated Somatotroph Tumors of Pituitary. World Neurosurg. 2024. https://doi.org/10.1016/j.wneu.2024.02.115.; Gadelha MR, Kasuki L. Refractory somatotroph adenomas. Pituitary. 2023;26(3):266–268. https://doi.org/10.1007/s11102-023-01324-5.